Member Info for BOJO2020

Blinkin Nora Batty EC... Half of the posts on the Angle BB today are you asking yourself a question and then answering it! Not your fault I suppose...

Clearly both trials must be mentioned but anything fresh? Probably not unless we get an RNS. Would like to know how Modi is fairing...

ATB

Don't get me wrong, love an investor presentation but why? Does Scancell have something apart from the ordinary to say

Well, if Modi can start to perform more like SCIB1 could get very interesting. But I am not banking on that. Would be a very nice bonus indeed.

Which means subsequent applications will be much simpler. But just imo Angle would be better of grabbing low hanging fruit as preciously explained

Because it achieved 510k first time…

HI Davey,

Good post. The only other one you missed was when it jumped from 11p to 28p last year! This just underlines your point. With expected news flow it is plausible to suggest that it may move upwards again in an equally significant way?

ATB

Nearly a penny spread

*flawed

In ANY AIM Co it is potential vs reality. That is until potential matches reality too break even, profitability, or not. What you are saying is that this principle is floored. My question is why are you bothered.

TGTD, I will put forward the following facts:

DDR assay developed for Artois for which Angle were paid and now Angle are actively marketing to other customers!

Her2 assay developed for Eisai (Japan) for which Angle will be paid £250k - this is a favourite of derampers 🤡. Who knows, it could lead to a bigger contract?

All I would say is Angle are picking the low hanging fruit and thank goodness they are and not reaching for all cancer validation. That would be nuts 🐿️

Re NGS. Dunno. They have said they have work to do on this and that is the way I read things first time reading the RNS. I was actually surprised that news did so well but it took me a little time to fully appreciate. I am sure you will feel the same way too at some point.

ATB

Last time you said 10p JS this went 37p

Really? 24 cancer types? One step at a time...The FDA already told Angle to rethink a whole cancer approach and address each cancer type one at a time. Would cost billions to tackle all cancers!

TGTD,

You talk about financial realities but with a long term view. You do not however acknowledge the potential and May I remind you that this share hit 37p a couple of weeks ago based on potential. Imo your posts lack balance and you in fact require others to make the balance for you. When people do you argue and talk down to people. So basically people ignore you I guess?

What I am wondering is besides the two NGS systems (illumina and Thermo Fisher which have been named dropped recently by AN and IG) are there any other NGS systems that Angle could use or are there any other none NGS platforms that could be used and which would offer particular benefits and limitations. So essentially, what is the thinking that Angle has had to undertake to present the best results. Sorry if that is a massive question. It may well just be one of the lead NGS systems which would be fine wouldn't it.

Mia,

You are right to underline Angles strategy of utilising the installed base of some 3000+ NGS systems. If Parsortix is a seamless fit why not! Also the economy point you make re: Ziplex is spot on thanks.

I also wonder what the benefits or limitations might be of choosing NGS to process these samples. It is clear that after using its own in house molecular system that Angle have to get this right so that the results are beyond dispute

Popeye a placing wont hurt as there are only 260 million shares in issue.

ATB

From today's RNS:

Harvested CTCs also have the added advantage in that they can undergo RNA, protein, and morphological analysis, thus combining genotype with phenotype to give a comprehensive biomarker profile. These recent advances in molecular oncology, combined with broad phenotyping including protein expression and analysis of methylation patterns are driving the implementation of precision oncology, with the aim of improving patient care.

AN mentioned in the recent proactive one2one that Angle were looking at the stored samples for prostate and ovarian being tested by third party systems. He mentioned NGS in the same breath so I am wondering if either Illumina or Thermo Fisher will be chosen as the third party platform as both dominate NGS and can be used for molecular analysis. Presumably there would be a cost attached to using either system if Angle do not have them readily installed?

Thanks chester

And the other question is, do we prove it up or do they. Might sound like a daft question but really important chicken and egg kind of thing. Also re costs and development.

ATB

Following on re AvidiMab. If I company were taking a look at it re: suitability at what stage of work would we expect an RNS? Is it possible that some preclinical testing would not require disclosure to the market?